Previously approved antibiotic helped kill Lyme disease-resistant bacteria

An approved antibiotic can completely eliminate the cause of Lyme disease – that is, destroy the main bacteria that cause the disease in mice. This is stated in a study by scientists from Stanford University, whose work is published in the journal Scientific Reports.

According to the Center for Disease Control and Prevention (CDC), Lyme disease is a tick-borne infectious disease that infects up to 5–7 thousand people a year in Russia.

Today, the treatment of this disease is largely effective when using antibiotics, but a significant proportion of patients (from 10 to 20%) do not respond to them and continue to experience some symptoms. These include muscle pain, weakness, fever, headaches, and heart problems.

“Some researchers believe that this may be due to the activity of drug-resistant bacteria that live in the body and continue to cause symptoms of the disease. Others believe that this is an immune disorder that bacteria cause during their first exposure to the human body. Regardless of the cause, pain for patients is still a real problem that needs to be addressed”.

Jayakumar Rajadas, lead author of the study

In an attempt to find a solution to this problem, scientists examined about 8 thousand different chemical compounds to make a list of candidates for a potential alternative treatment for Lyme disease, and then tested them on laboratory mice.

Researchers found that of all the drugs they tested and tested, azlocillin was found to be the most effective at killing the bacteria that caused Lyme disease – Borrelia burgdorferi. During experiments in mice, where the drug was administered to animals at intervals of 7, 14, and 21 days, scientists found that the antibiotic completely kills the bacteria.

The authors of the works note that the drug also proved to be effective in the destruction of drug-resistant forms of B. burgdorferi in laboratory cups. In the near future, the authors of the study intend to consolidate the results of their work, and then proceed to clinical testing of the drug in patients with Lyme disease.

Author: Flyn Braun
Graduated from Cambridge University. Previously, he worked in various diferent news media. Currently, it is a columnist of the us news section in the Free News editors.
Function: Editor